Breaking News

Granuflo Lawsuit Update

law

GlaxoSmithKline Lawsuit Update

Last week’s release of the Granuflo lawsuit update caused quite a stir in the natural health community. The Natural Health Care Association of America, or NHCAA, released an article describing the lawsuit as “a serious example of pharmaceutical fraud.” They claimed that the claims made by Granuflo violated FDA policy. However, the FDA has made it clear that their policy only prohibits the use of unapproved or misbranded drugs in the manufacture and distribution of dietary supplements.

Granuflo Lawsuit Update

According to the attorney for the plaintiffs in the suit, the manufacturers knew or should have known that their naturalyte dialysis treatments were ineffective. Yet, they knowingly and negligently sold millions of doses of the medicine to unknowing patients.

As a result of this action, innocent individuals who suffered from cardiac arrest, stroke, heart attacks, and other debilitating medical conditions have been placed at risk of experiencing more expensive medical treatments that could have been avoided by taking the safer and more effective medication.

This is not the first case involving the sale and distribution of this product.

In 2021, a federal jury awarded a $4.35 million verdict against GlaxoSmithKline (GSK), the manufacturer of Granuflo. The verdict was based on the claim that the company failed to warn its customers of the potential side effects associated with taking the medication.

The plaintiffs in this case suffered cardiac arrests, strokes, congestive heart failure, cardiomyopathy, and neuromuscular disease as a result of taking Granuflo. A class action lawsuit was eventually brought on behalf of all the individuals that had undergone these life-altering medical situations. Although the company has already paid compensation to those who suffered cardiac arrest, stroke, and congestive heart failure, they are appealing the verdict.

The reason that this case has become newsworthy is that it is not the first time that a large number of individuals have claimed that they have suffered from side effects from taking Granuflo.

In fact, it is estimated that thousands of people will suffer from these ailments throughout the course of this lawsuit. What makes this type of lawsuit different is that instead of simply being the victim of a dangerous pharmaceutical, the person bringing the suit is seeking monetary compensation for the fear that they may develop even death from using the meds.

It is believed that thousands of people who suffer from medical conditions such as high blood pressure, congestive heart failure, high cholesterol, sleep apnea, or kidney failure may have actually died as a result of the drugs.

The attorneys that are involved in these lawsuits work very hard to ensure that their clients receive fair representation.

They do this by gathering all of the information that is necessary to ensure that their client receives fair representation and by putting together a strong case that is backed up with medical records and other expert testimony. One of the main reasons that these lawsuits are so damaging to GlaxoSmithKline is because it is one of the most popular brands of diet and health supplements in the world.

There are countless numbers of people that rely on the safety and effectiveness of Granu Flo diet and health supplements. This can make it very difficult for the plaintiffs’ attorney to prove that the manufacturer knew about the possibility of the side effects that were occurring among its consumers.

The recalls and the lawsuits do not seem to be slowing down GlaxoSmithKline.

Currently, the company is responsible for more than twenty recalls, including that of the diet and health supplement line. As time goes on, we can only expect to see more of these lawsuits and recalled products. While there is no definite timeline set in stone as to when the GlaxoSmithKline recall will end, it is safe to say that the lawsuits are only going to get bigger and stronger.

Leave a Reply

Your email address will not be published. Required fields are marked *